The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.

Usually, the shingles rash occurs on the chest and tummy ... Other names from sepsis include septicaemia or blood poisoning. Treatment in hospital is essential straight away as the skin condition can ...

Research into new bandaging aims to ease the agony experienced by those living with genetic skin condition Epidermolysis Bullosa (EB), commonly referred to as 'butterfly skin'.

Heat rash, a skin condition common during summer ... see a doctor for further evaluation and treatment.

Jasper Therapeutics faces financial challenges but strong buy ratings. Read why JSPR stock is poised for growth amid risks ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Milk protein allergy (MPA), also known as food protein induced allergic proctocolitis (FPIAP), is one of the most common ...

French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

We tend to think of COVID-19 as a respiratory illness. But, like many viruses, COVID can also affect your skin and cause ...

Medically reviewed by Jurairat J. Molina, MD Acute urticaria (hives) is a common skin condition that affects up to 20% of people at some point in their lives. It can transition into chronic urticaria ...